Final Phase III Study Results Confirm Benefit of Praxbind® as Rever
Complete data set from 503 patients show that Praxbind (idarucizumab) led to...
2017-07-12
文传商讯
Updated Phase III Results Reinforce Safety and Efficacy of Praxbind®
Idarucizumab immediately reversed the anticoagulant effect of dabigatran in ...
2016-11-17
文传商讯
Boehringer Ingelheim launches RE-VECTO global program to capture data o
Praxbind® (idarucizumab) is the specific reversal agent for the oral ant...
2016-08-16
文传商讯
Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabig
A single 5g dose of idarucizumab immediately reversed the anticoagulant effe...
2016-04-06
文传商讯
